Moderna, GSK and COVID-19
GSK sues Moderna over mRNA vaccine technology
GlaxoSmithKline is suing Moderna for allegedly using technology patented by GSK in its COVID-19 vaccine. Why it matters: It's the latest in a series of legal fights over who owns the intellectual property behind mRNA technology and whether some companies are entitled to royalties on future sales.
GlaxoSmithKline sues Moderna for US patent infringement over COVID vaccines
GlaxoSmithKline sued Moderna in Delaware federal court on Tuesday for allegedly violating GSK's patent rights in messenger RNA (mRNA) technology with its blockbuster COVID-19 vaccine Spikevax. The lawsuit said Moderna's lipid nanoparticles for transporting mRNA into the human body infringe several GSK patents covering similar innovations.
GSK sues Moderna over US patent violation of Spikevax COVID-19 vaccine
A Moderna spokesperson said the company was aware of the new litigation and would defend itself against the claims
GSK Sues Moderna Over mRNA Vaccine Patents
GlaxoSmithKline (GSK) has filed a patent infringement lawsuit against Moderna in Delaware, accusing the company of using its patented mRNA technology in their Spikevax COVID-19 vaccine without permission.
Northwestern sues Moderna for patent infringement over COVID-19 vaccines
Moderna was hit with a new patent lawsuit on Wednesday in Delaware federal court from Northwestern University, which accused the company of misusing the school's innovations to develop its blockbuster COVID-19 vaccine Spikevax.
Northwestern sues Moderna for alleged patent infringement in COVID shots
Moderna is facing allegations that it misused innovations from researchers at Northwestern University to develop its mRNA COVID-19 vaccines, which became widely available to the public in 2021 to combat the pandemic.
British drugmaker sues Moderna for patent infringement related to mRNA vaccines
A British drugmaker, GlaxoSmithKline (GSK), has sued American pharmaceutical company Moderna claiming it violated patent rights in its mRNA technology used to develop its COVID-19 and RSV vaccines.
FiercePharma1d
With Gilead coming fast, GSK bolsters case for long-acting HIV PrEP drug Apretude
With Gilead sprinting to a likely approval next year for its long-acting pre-exposure | With GSK girding for competition from ...
devdiscourse2d
Patent Wars: GSK Takes on Moderna Over mRNA Innovations
GlaxoSmithKline has filed lawsuits against Moderna in a Delaware federal court, alleging infringement of patents related to ...
GlaxoSmithKline Settles Most Zantac Lawsuits for $2.2B
The settlement, announced on Wednesday, resolves 93% of all Zantac cases in state courts against GlaxoSmithKline.
GSK jumps 6% after $2.2B Zantac settlement: why analysts see more upside
GlaxoSmithKline (GSK) saw its shares jump more than 6% after the pharmaceutical giant announced a settlement of up to $2.2 ...
manilastandard3d
GSK gets FDA approval for meningococcal vaccine
Pharmaceutical firm GlaxoSmithKline (GSK) announced Tuesday it received approval from the Food and Drug Administration (FDA) ...
Reuters2d
GSK sues Moderna for US patent infringement over COVID, RSV vaccines
Moderna to defend against GSK's claims, spokesperson says GSK seeks unspecified monetary damages from Moderna A spokesperson for Massachusetts-based Moderna said the company was aware of the ...
GSK rises Thursday, still underperforms market
GSK PLC GSK shares inched up 0.03% to £14.97 Thursday, on what proved to be an all-around favorable trading session for the ...
GSK Seeks FDA Approval For Oral Antibiotic For Urinary Tract Infections, Probably First In New Class In Over 20 Years
GSK's gepotidacin, an oral antibiotic for uUTIs, could be the first in over 20 years. The FDA granted Priority Review with a ...